Metabolomics analysis identifies different metabotypes of asthma severity

European Respiratory Journal

Volumn 49, Issue 3, 2017, Pages

  Reinke, Stacey N ^a   Gallart Ayala, Héctor ^a   Gómez, Cristina ^a   Checa, Antonio ^a   Fauland, Alexander ^a   Naz, Shama ^a   Kamleh, Muhammad Anas ^a   Djukanović, Ratko ^b,c   Hinks, Timothy S C ^b,c,d   Wheelock, Craig E ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; CORTISONE; HYDROCORTISONE; HYDROXYPROLINE; N OLEOYLETHANOLAMINE; N PALMITOYLTAURINE; PIPECOLIC ACID; PRASTERONE SULFATE; PROLYLHYDROXYPROLINE; TAURINE DERIVATIVE; UNCLASSIFIED DRUG; CORTICOSTEROID;

ADULT; ARTICLE; ASTHMA; BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; METABOLOMICS; PRIORITY JOURNAL; CASE CONTROL STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INHALATIONAL DRUG ADMINISTRATION; MASS SPECTROMETRY; METABOLISM; METABOLOME; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADULT; ASTHMA; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 85034765323     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01740-2016     Document Type: Article

References (46)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2012. www.ginasthma.org Date last accessed: 5 September 2013.
2. Gauthier M, Ray A, Wenzel SE. Evolving concepts of asthma. Am J Respir Crit Care Med 2015; 192: 660–668.
3. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex. heterogeneous disease. Lancet 2008; 372: 1107–1119.
4. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373.
5. Dunn WB, Broadhurst DI, Atherton HJ, et al. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev 2011; 40: 387–426.
6. Broadhurst DI, Kell DB. Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2006; 2: 171–196.
7. Holmes TH. Ten categories of statistical errors: a guide for research in endocrinology and metabolism. Am J Physiol Endocrinol Metab 2004; 286: E495–E501.
8. Jung J, Kim SH, Lee HS, et al. Serum metabolomics reveals pathways and biomarkers associated with asthma pathogenesis. Clin Exp Allergy 2013; 43: 425–433.
9. Ried JS, Baurecht H, Stuckler F, et al. Integrative genetic and metabolite profiling analysis suggests altered phosphatidylcholine metabolism in asthma. Allergy 2013; 68: 629–636.
10. Loureiro CC, Duarte IF, Gomes J, et al. Urinary metabolomic changes as a predictive biomarker of asthma exacerbation. J Allergy Clin Immunol 2014; 133: 261–263.
11. Saude EJ, Skappak CD, Regush S, et al. Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy. J Allergy Clin Immunol 2011; 127(3): 757–764.
12. Comhair SA, McDunn J, Bennett C, et al. Metabolomic endotype of asthma. J Immunol 2015; 195: 643–650.
13. Hinks TS, Zhou X, Staples KJ, et al. Innate and adaptive T cells in asthmatic patients: relationship to severity and disease mechanisms. J Allergy Clin Immunol 2015; 136: 323–333.
14. Vijayanand P, Seumois G, Pickard C, et al. Invariant natural killer T cells in asthma and chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 1410–1422.
15. Dunn WB, Broadhurst D, Begley P, et al. Human serum metabolome C. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 2011; 6: 1060–1083.
16. Kirwan JA, Broadhurst DI, Davidson RL, et al. Characterising and correcting batch variation in an automated direct infusion mass spectrometry (DIMS) metabolomics workflow. Anal Bioanal Chem 2013; 405: 5147–5157.
17. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. 2nd Edn. New York, Springer, 2009.
18. Hollywood KA, Winder CL, Dunn WB, et al. Exploring the mode of action of dithranol therapy for psoriasis: a metabolomic analysis using HaCaT cells. Mol Biosyst 2015; 11: 2198–2209.
19. Krzanowski WJ. Principles of Multivariate Analysis: A User’s Perspective. Oxford, Oxford University Press, 1988.
20. Troyanskaya O, Cantor M, Sherlock G, et al. Missing value estimation methods for DNA microarrays. Bioinformatics 2001; 17: 520–525.
21. Peres-Neto PR, Jackson DA, Somers KM. Giving meaningful interpretation to ordination axes: assessing loading significance in principal component analysis. Ecology 2003; 84: 2347–2363.
22. Levy BD. Sphingolipids and susceptibility to asthma. N Engl J Med 2013; 369: 976–978.
23. McGeachie MJ, Dahlin A, Qiu W, et al. The metabolomics of asthma control: a promising link between genetics and disease. Immun Inflamm Dis 2015; 3: 224–238.
24. Nikolaizik WH, Marchant JL, Preece MA, et al. Nocturnal cortisol secretion in healthy adults before and after inhalation of budesonide. Am J Respir Crit Care Med 1996; 153: 97–101.
25. Clark DJ, Grove A, Cargill RI, et al. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996; 51: 262–266.
26. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002; 2: 748–759.
27. Yeh YY, Liu L. Cholesterol-lowering effect of garlic extracts and organosulfur compounds; human and animal studies. J Nutr 2001; 131: Suppl. 3, 989S–993S.
28. Jalal MAF, Collin HA. Estimation of caffeine, theophylline, and theobromine in plant material. New Phytol 1975; 76: 277–281.
29. Li M, Wang B, Zhang M, et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA 2008; 105: 2117–2122.
30. Nagel G, Linseisen J. Dietary intake of fatty acids. antioxidants and selected food groups and asthma in adults. Eur J Clin Nutr 2005; 59: 8–15.
31. Huang YJ, Boushey HA. The microbiome in asthma. J Allergy Clin Immunol 2015; 135: 25–30.
32. Brinkmann V, Baumruker T. Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Curr Opin Pharmacol 2006; 6: 244–250.
33. Trankner D, Hahne N, Sugino K, et al. Population of sensory neurons essential for asthmatic hyperreactivity of inflamed airways. Proc Natl Acad Sci USA 2014; 111: 11515–11520.
34. Wang X, Miyares RL, Ahern GP. Oleoylethanolamide excites vagal sensory neurones. induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1. J Physiol 2005; 564(Pt 2): 541–547.
35. Saghatelian A, McKinney MK, Bandell M, et al. A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry 2006; 45: 9007–9015.
36. Lee LY, Gu Q. Role of TRPV1 in inflammation-induced airway hypersensitivity. Curr Opin Pharmacol 2009; 9: 243–249.
37. McGarvey LP, Butler CA, Stokesberry S, et al. Increased expression of bronchial epithelial transient receptor potential vanilloid 1 channels in patients with severe asthma. J Allergy Clin Immunol 2014; 133: 704–712 e704.
38. Limm K, Wallner S, Milenkovic VM, et al. The metabolite 5′-methylthioadenosine signals through the adenosine receptor A2B in melanoma. Eur J Cancer 2014; 50: 2714–2724.
39. Szallasi A, Cortright DN, Blum CA, et al. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 2007; 6: 357–372.
40. Burnstock G, Sawynok J. Adenosine triphosphate and adenosine receptors and pain. In: Beaulieu P, Lussier D, Porreca F, Dickenson A, eds. Pharmacology of Pain. Seattle, IASP Press, 2010; pp. 303–326.
41. Aherne CM, Kewley EM, Eltzschig HK. The resurgence of A2B adenosine receptor signaling. Biochim Biophys Acta 2011; 1808: 1329–1339.
42. Raissy HH, Kelly HW, Harkins M, et al. Inhaled corticosteroids in lung diseases. Am J Respir Crit Care Med 2013; 187: 798–803.
43. Kannisto S, Laatikainen A, Taivainen A, et al. Serum dehydroepiandrosterone sulfate concentration as an indicator of adrenocortical suppression during inhaled steroid therapy in adult asthmatic patients. Eur J Endocrinol 2004; 150: 687–690.
44. Husek P, Svagera Z, Vsiansky F, et al. Prolyl-hydroxyproline dipeptide in non-hydrolyzed morning urine and its value in postmenopausal osteoporosis. Clin Chem Lab Med 2008; 46: 1391–1397.
45. Moayyeri A, Hart D, Erte I, et al. Causal metabolomic pathways to osteoporosis in elderly women. In: European Calcified Tissue Society Congress; 18–21 May 2013; Lisbon, Portugal. Bone Abstracts 2013; 1: OC3.6.
46. Wong CA, Walsh LJ, Smith CJ, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 2000; 355: 1399–1403.